bms-3

BMS-3 is a potent LIMK inhibitor with IC50 values of 5 nM and 6 nM for LIMK1 and LIMK2, respectively.

BMS-363131 (BMS363131) is a potent and selective trypsin inhibitor with an IC50 value of <1.7 nM.

BMS-394136 (BMS 394136) is a KV1.5 antagonist for the treatment of cardiovascular diseases such as arrhythmias and atrial fibrillation.

BMS-345541 (IKK Inhibitor III) is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM, respectively.

BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor (IC50: 0.13 uM, human recombinant ACL).

BMS-378806 is a novel attachment inhibitor of HIV (EC50: 2.68±1.64nM, 26.5±3.5nM, 2.94±2.01nM,15.5±6.8nM, 3.46±0.81nM, 1.47±0.63nM and 0.85±0.13nM for LAI(T), SF-2(T),NL4-3(T), Bal(M), SF-162(M), JRFL(M) and TLAV(dual), respectively).

BMS-309403 sodium is a potent, orally active, selective inhibitor of adipocyte fatty acid binding protein (FABP4, aP2), with inhibitory constants (Ki) of <2 nM for FABP4, 250 nM for FABP3, and 350 nM for FABP5. It competitively binds to the fatty-acid-binding pocket of the protein, impeding the attachment of endogenous fatty acids. This compound enhances endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells, underlining its potential therapeutic benefits [1] [2] [3].

BMS-341400 mesylate (Compound 6) is an orally active selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 value of 0.3 nM and is useful in the study of erectile dysfunction.

BMS-317180 is a potent, novel, orally effective growth hormone secretagogue (GHS) that shows an excellent safety profile in preclinical studies. The compound was advanced into clinical development.

BMS-344577, a lactam derivative based on arylguanidine, is a potent oral active FXA inhibitor with excellent susceptibility in vitro, good pharmacokinetics, and pharmacodynamics in animal models.

BMS-346567 is a potent and selective dual angiotensin II and endothelin receptor antagonist.

BMS-347070 is a COX-2 inhibitor.

BMS-354326 is a bio-active chemical.

BMS-358233 is an effective LCK inhibitor with excellent cell activity against T cell proliferation.

BMS309403 is a potent and selective inhibitor of adipocyte fatty acid binding protein aFABP. It improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. It interacts with the fatty acid binding pocket inside the protein and competitively inhibits the binding of endogenous fatty acids.

BMS-378806 (BMS-806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.

BMS-37 is a novel inhibitor of PD-1 PD-L1 immune checkpoint.

BMS-351 is a potent and selective, nonsteroidal CYP17A1 lyase inhibitor with robust selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 emerges as an outstanding preclinical candidate to treat CRPC and is likely to minimize the side effects of current therapies due to its exceptional selectivity. BMS-351 is potentially useful for the Treatment of Prostate Cancer.

BMS-332 is a dual inhibitor of the lipid kinases DGKα and DGKζ, demonstrating half-maximal inhibitory concentrations (IC50) of 0.005 μM for DGKα and 0.001 μM for DGKζ [1].

BMS-345541 hydrochloride is a selective IKK inhibitor, targeting IKK2 and IKK1 with IC50 values of 0.3 μM and 4 μM, respectively.

BMS-337197 is an IMPDH inhibitor.

Linrodostat (BMS-986205) is a selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).

BMS-906024 (Osugacestat) is an orally available and selective inhibitor of γ-secretase, a small molecule Notch inhibitor.BMS-906024 has broad-spectrum antitumour activity against a variety of human cancer xenografts.BMS-906024 prevents the activation of all four Notch receptors, and is active against Notch1, -2, -3 and -4 receptors. BMS-906024 prevents the activation of all four Notch receptors, with IC50s of 1.6, 0.7, 3.4 and 2.9 nM for Notch1, -2, -3 and -4 receptors, respectively.

Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035 1.3 4.6 7 11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.